S3 Table. Predictability of circulating TNFRs on clinical outcome classified by the immunosuppressive (IS) treatment

IS (+)		Model 1[a]		Model 2[b]	
		HR (95% CI)	*P*	HR (95% CI)	*P*
TNFR1	Q1-3 (reference)	1.00		1.00	
	Q4	9.14 (1.85-45.13)	0.007	8.74 (1.77-43.06)	0.008
TNFR2	Q1-3 (reference)	1.00		1.00	
	Q4	7.06 (1.46-34.19)	0.015	6.75 (1.40-32.58)	0.017
IS (-)		Model 1[a]		Model 2[b]	
		HR (95% CI)	*P*	HR (95% CI)	*P*
TNFR1	Q1-3 (reference)	1.00		1.00	
	Q4	13.47 (6.09-29.81)	<0.001	9.74 (4.16-22.78)	<0.001
TNFR2	Q1-3 (reference)	1.00		1.00	
	Q4	5.78 (2.82-11.84)	<0.001	3.79 (1.72-8.33)	0.001

[a] Unadjusted model

[b] Model 1 + adjustment for gender, age, systolic blood pressure, eGFR, urine protein-creatinine ratio, and the quartiles of concentrations of cTNFRs

TNFR, tumor necrosis factor receptor